ALKS

34.53

2.27% 0.765

Dopo l'orario di chiusura: 34.59 0.06 +0.17%

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$33.77

Aprire:

$34.52

Volume 24 ore:

2.22M

Relative Volume:

0.94

Capitalizzazione di mercato:

$5.74B

Reddito:

$1.48B

Utile/perdita netta:

$241.66M

Rapporto P/E:

24.10

EPS:

1.4325

Flusso di cassa netto:

$480.33M

1 W Prestazione:

+3.51%

1M Prestazione:

+24.88%

6M Prestazione:

+14.11%

1 anno Prestazione:

+27.89%

Intervallo 1D:

$34.11

$34.72

Intervallo di 1 settimana:

$32.76

$34.72

Portata 52W:

$25.16

$36.48

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1116)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

2,050

Cinguettio

@alkermes

Prossima data di guadagno

2026-05-07

Ultimi documenti SEC

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	34.53	5.74B	1.48B	241.66M	480.33M	1.4325
TAK Takeda Pharmaceutical Co Adr	17.82	56.30B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	122.38	51.46B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.75	43.42B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.40	37.73B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	588.38	25.79B	3.18B	1.33B	1.04B	27.90

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2025-11-11	Iniziato	Truist	Buy
2025-09-26	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Iniziato	Wells Fargo	Overweight
2025-07-15	Iniziato	Goldman	Buy
2025-06-17	Aggiornamento	UBS	Neutral → Buy
2025-05-28	Iniziato	Needham	Buy
2025-03-13	Iniziato	RBC Capital Mkts	Sector Perform
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

Apr 19, 2026

Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN

Apr 19, 2026

(ALKS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 19, 2026

Apr 18, 2026

Avadel Stock Rises After Acquisition Offer By Alkermes - MSN

Apr 18, 2026

Alkermes plc stock (IE00B56GVS15): Is its neuroscience focus strong enough to drive steady upside? - AD HOC NEWS

Apr 18, 2026

Apr 17, 2026

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting - BioSpace

Apr 17, 2026

Apr 16, 2026

Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN

Apr 16, 2026

Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities - CSRwire

Apr 16, 2026

Alkermes (ALKS) Unveils Promising Data on Alixorexton for Narcol - GuruFocus

Apr 16, 2026

Alkermes to present narcolepsy drug data at neurology meeting - Investing.com

Apr 16, 2026

Alkermes to present narcolepsy drug data at neurology meeting By Investing.com - Investing.com Canada

Apr 16, 2026

Narcolepsy patients showed 13 weeks of gains in Alkermes study - Stock Titan

Apr 16, 2026

Robeco Institutional Asset Management B.V. Purchases 151,283 Shares of Alkermes plc $ALKS - MarketBeat

Apr 16, 2026

ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill

Apr 16, 2026

Apr 14, 2026

Alkermes (ALKS) Reveals Positive Findings on Lybalvi for Schizop - GuruFocus

Apr 14, 2026

Alkermes publishes 56-week study on Lybalvi negative symptoms By Investing.com - Investing.com Australia

Apr 14, 2026

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry - BioSpace

Apr 14, 2026

Alkermes publishes 56-week study on Lybalvi negative symptoms - Investing.com

Apr 14, 2026

Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI - Stock Titan

Apr 14, 2026

Apr 13, 2026

Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative? - simplywall.st

Apr 13, 2026

Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan

Apr 13, 2026